TIDMCREO

RNS Number : 6769N

Creo Medical Group PLC

10 May 2018

Creo Medical Group plc

Exercise of Options

Chepstow, Wales - 10 May 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, confirms that it has issued, conditional on admission, 20,000 new ordinary shares of GBP0.001 each in the capital of Creo (the "New Shares"), pursuant to an exercise of share options.

Application has been made to the London Stock Exchange for admission of the New Shares to trading on AIM and dealings are expected to commence on 17 May 2018 ("Admission"). Following Admission, Creo will have a total of 81,123,065 ordinary shares of GBP0.001 each in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in Creo.

Contacts

 
 Creo Medical:          Cenkos:                 FTI Consulting: 
 Richard Rees           Camilla Hume/Mark       Brett Pollard / Mo 
  +44 (0)129 160 6005    Connelly (NOMAD)        Noonan 
                         Michael Johnson /       +44 (0)203 727 1000 
                         Russell Kerr (Sales)    creo@fticonsulting.com 
                         +44 (0)207 397 8900

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEMMGMKGGNGRZM

(END) Dow Jones Newswires

May 10, 2018 06:25 ET (10:25 GMT)

Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Creo Medical Charts.
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Creo Medical Charts.